WhatsApp, WeChat & Telegram : +8801886229488, Email : email@example.com
Ponatinix (Ponatinib) 15/45 mg
Generic Name: Ponatinib
Manufacturer: Beacon pharma
Tablet: 30’s Pot / 60’s Pot
Originator: Iclusig by Ariad Pharma
Contact For Order:
WhatsApp & WeChat: +8801886229488
WeChat QR Code
Ponatinix (Ponatinib) is used to treat Blood Cancer. the overall survival rate is 80.5%. Once daily convenient dose. ponatinix manufactured by beacon pharma.
FAQ about Ponatinix (Ponatinib)
Q: What is Ponatinix (Ponatinib) used for?
It is a treatment for some types of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).
Q: What generation is ponatinib?
Ponatinib: A Third-Generation Inhibitor for the Treatment of CML.
Q: Is ponatinib a chemotherapy drug?
Ponatinib is not a chemotherapy drug but one of many “targeted therapies.” Targeted therapy is the result of about 100 years of research dedicated to understanding the differences between cancer cells and normal cells.
Q: How effective is ponatinib?
The ponatinib initial daily dose was 45 mg in 60% of patients, 30 mg in 38% and 15 mg in 2% of patients. After a median time of 12 months, 85% of patients achieved a better molecular response compared with the baseline. Among them, 10 (40%) patients achieved a deep molecular response. No AOEs were observed (Table 2)
Ponatinix, is an oral drug under the generic of Ponatinib, for the first-line therapy of the people affected with chronic myelogenous leukemia.
It is a highly potential and multi-targeted third generation Bcr-Abl tyrosine-kinase inhibitors (TKI) which is indicated for the adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) or Ph+ALL for those who have no other TKI therapy.
It is also indicated for the adult patients with T315I-positive CML (chronic phase, accelerated phase of blast phase) or T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL).
|Available Pack Size||:||60’s pot|
|Available Strength||:||15 mg|
There are no reviews yet.